To analyze the emerging global market for mesenchymal stem cells (MSCs), it is important to define the cell type. Broadly defined, mesenchymal stem cells are multi-potent stem cells that can differentiate into a diverse range of cell types. More specifically, mesenchymal stem cells are non-hematopoietic stromal cells that are capable of differentiating into, and assisting in the repair of, tissues of both intra-mesenchymal and extra-mesenchymal lineages.
Mesenchymal stem cells are a class of multipotent cells found in human tissues, such as bone marrow, adipose tissue, dental pulp, and periosteum, a layer of connective tissue that envelops the bones. They are also known as: Medicinal Signaling Cells, Mesenchymal Stromal Cells, and Marrow Stromal Cells. Given this naming variability, as well as urging by Dr. Caplan to rename the cells so that patients don’t assume specific medical benefits, these cells are best known as: MSCs. [Read more…]
The “Global Cord Blood Banking Industry Report” reveals key benchmarks to track and why you should care. Benchmarks are critical to assess, because the cord blood banking industry has matured substantially over the past few years, creating both serious threats and novel opportunities.
Therefore, judging individual company performance relative to the broader cord blood marketplace has become substantially more complex.
Mesenchymal stem cells (MSCs) have inspired a great deal of activity as a novel therapeutic approach. Presently, MSC-based clinical trials are being conducted for a variety of disease conditions, with many trials demonstrating safety and efficacy.
Clinical utility of MSCs can be attributed to four key biological properties:
- Their potential to migrate to sites of inflammation caused by tissue injury when injected intravenously
- Their potential to differentiate into different cell types
- Their potential to release different bioactive molecules that can stimulate the recovery of injured cells
- Their ability to modulate inflammation and accomplish immunomodulatory functions
Currently, several hundred MSC clinical trials are in progress across different parts of the world, including within the U.S. European Union (EU), China, Middle East, and South Korea. Among these clinical trials, approximately one-third are exploiting MSCs for various disease indications. Unfortunately, only a small number of clinical trials using MSCs have reached Phase III, indicating that the therapeutic potential for MSCs has yet to be realized.
One of the major bottlenecks to the industry is how to manufacture clinical-grade MSCs on a commercial scale, which Australian regenerative medicine company Cynata Therapeutics (ASX:CYP) is aiming to solve.
To fully understand the cell type and its evolution over time, this post considers key dates in the discovery of mesenchymal stem cells (MSCs). [Read more…]
MIAMI, May 10, 2017 — Longeveron, a regenerative medicine company, announced that their Phase 1 Alzheimer’s disease trial will proceed with enrollment at the recommendation of an independent Data Monitoring Committee (DMC) which reviewed data from the trial’s safety run-in phase.
The clinical trial is designed to assess the safety, tolerability and efficacy of intravenous infusion of two different doses of Longeveron mesenchymal stem cells (LMSCs) compared to placebo. The DMC reviewed safety data from a five-patient run-in phase where subjects diagnosed with Alzheimer’s disease were given a single infusion of either LMSCs or placebo. Longeveron now has the green light to continue the trial.